RESEARCH GUIDE / PUBLISHED
What the study actually tested
Read models, controls, sample size, outcomes, uncertainty, harms, registration, and published results as separate parts of one study story.
Start with the model
A cell experiment can isolate a pathway under controlled conditions. An animal model can study interacting organs, exposure, or behavior in a living system. A human study can observe people, but its answer still belongs to the enrolled population, tested intervention, comparator, route, duration, and outcomes.
Each model can be useful without being interchangeable. Cells are not small people, and an animal disease model is not the human condition itself. Translation is a new question that needs new evidence, not a label added to an earlier result.
Section sources: NIH principles and guidelines for reporting preclinical research; ARRIVE guidelines 2.0
Controls, randomization, and masking
A control group helps estimate what would have happened without the tested change. Random allocation can reduce systematic differences between groups, while masking can reduce the chance that expectations influence care, measurement, exclusions, or analysis. The exact methods matter more than the presence of reassuring words in an abstract.
Not every question permits the same design, but departures need explanation. NIH preclinical guidance and ARRIVE reporting guidance both emphasize reporting randomization, blinding, exclusions, and the steps used to reduce bias and confounding.
Section sources: NIH principles and guidelines for reporting preclinical research; ARRIVE guidelines 2.0
Sample size is about information
A small study can detect a large, consistent signal or reveal feasibility problems; it usually cannot estimate modest effects or uncommon harms precisely. A large sample does not rescue a biased comparison, a poor measurement, or an outcome chosen after looking at the data.
Look beyond a p-value. Effect size, confidence interval, event counts, missing data, and the analysis population show how much uncertainty remains. Ask whether the sample-size rationale used the primary outcome and whether the study stopped early or changed course.
Section sources: CONSORT 2025 statement: updated guideline for reporting randomised trials; ARRIVE guidelines 2.0
Outcomes can be direct, surrogate, or exploratory
The primary outcome should be the study's main test, preferably specified in advance. Secondary and exploratory outcomes can add context but create more opportunities for chance findings. A biomarker or surrogate endpoint is not automatically equivalent to how a participant feels, functions, or survives.
Check the measurement time, definition, and denominator. ‘Improved’ may describe a laboratory value, a rating scale, an average difference, or fewer events; those are different claims. Captain Peptide asks what changed. Preppy Boy asks whether that was the outcome the study was built to test.
Section sources: CONSORT 2025 statement: updated guideline for reporting randomised trials; ClinicalTrials.gov: How to Read Study Results
Harms need complete denominators and follow-up
No adverse events reported can mean none occurred, none were detected, or reporting was incomplete. Look for the number exposed, duration, withdrawals, serious adverse events, prespecified collection methods, and differences between groups. Rare or delayed harms generally cannot be ruled out by a short or small study.
ClinicalTrials.gov results records separate participant flow, baseline characteristics, outcomes, and adverse events. That structure is a useful reading checklist even when the decisive information appears in a full publication.
Section sources: ClinicalTrials.gov: How to Read Study Results; CONSORT 2025 statement: updated guideline for reporting randomised trials
Registration is a plan; results are observations
A registry record can show the planned design, outcomes, enrollment, dates, sponsor, and edit history. Registration does not show that the study finished or that the intervention worked. Results may appear in a registry, a journal article, both, or neither.
Compare the earliest available plan with the final report. Check whether primary outcomes, time points, enrollment, exclusions, and analysis changed, and whether all prespecified outcomes and harms were reported. CONSORT 2025 supports transparent reporting, but a checklist cannot by itself prove that a study was well conducted.
Section sources: ClinicalTrials.gov: How to Read a Study Record; ClinicalTrials.gov: How to Read Study Results; CONSORT 2025 statement: updated guideline for reporting randomised trials
Build the narrowest justified conclusion
Summarize the tested model, intervention, comparator, sample, duration, primary result, uncertainty, harms, and major limitations in one paragraph. If the conclusion you are reading is broader than that paragraph, identify the extra inference.
One study can move a question forward. Replication, converging methods, and evidence in relevant populations make a conclusion sturdier. None of them verify the contents, quality, or suitability of an unrelated catalogue material.
Section sources: CONSORT 2025 statement: updated guideline for reporting randomised trials; NIH principles and guidelines for reporting preclinical research
